Novartis announced Wednesday it will construct a specialized cancer treatment manufacturing facility in Texas as part of a $23 billion U.S. expansion plan. The new plant will produce radioligand therapies, which deliver targeted radiation directly to cancer cells.
Swiss pharmaceutical company Novartis announced Wednesday its plans to construct a specialized manufacturing facility in Texas dedicated to producing advanced cancer treatments, marking the company’s first such operation in the Lone Star State.
The new facility represents part of Novartis’s massive $23 billion investment strategy to expand its American manufacturing presence, a move that comes as pharmaceutical companies worldwide work to strengthen domestic production capabilities amid increased tariffs on imported medications under the Trump administration.
Company CEO Vas Narasimhan emphasized the facility’s importance, stating: “The addition of our fifth RLT manufacturing site in the U.S. strengthens our ability to meet growing demand, building the capabilities needed to deliver these next-generation treatments with the speed and precision they require.”
The facility will focus on producing radioligand therapy treatments, an innovative approach to fighting cancer that uses targeted radiation delivered straight to cancerous cells. Novartis currently sells two such medications: Pluvicto, designed for prostate cancer patients, and Lutathera, which treats uncommon digestive system tumors.
Construction on the 46,000-square-foot facility in Denton, Texas is scheduled to commence this year, with full operations expected by 2028. The company anticipates the site will generate employment opportunities in bioengineering, sophisticated manufacturing processes, quality control, and operational management.
This Texas location will join Novartis’s current network of radioligand therapy production sites across New Jersey, Indiana, and California, plus a recently announced Florida facility.